Klinische bedeutung der echokontrastverstarkung in der neurovaskularen diagnostik: Erfahrungsbericht nach einjahriger offener anwendungsstudie

Translated title of the contribution: Clinical significance of echocontrast enhancement in neurosonology: Aim of the study

D. G. Nabavi, D. W. Droste, G. Schulte-Altedorneburg, V. Kemény, M. Panzica, S. Weber, E. B. Ringelstein

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To evaluate the potential and limitations of echocontrast enhancement using Levovist® in a non selected consecutive cohort of neurological patients with insufficient native ultrasound investigations. Methods: In 91 patients an indication for echocontrast application was seen after an insufficient extracranial (n = 17), transtemporal (n = 54), and transforaminal (n = 20) Doppler- und color-coded Duplex sonography. Levovist® was injected at a concentration of 400 mg/ml and 200-400 mg/ml for the transcranial and extracranial approach, respectively. The effect of the echocontrast enhancement was assessed semiquantitatively with respect to signal enhancement, imaging quality, and diagnostic confidence. Results: In a total of 83 patients (91%) the signal enhancement led to a moderate to high imaging quality allowing to reach 67 definite neurovascular diagnoses (74%). In subgroup analysis, the amount of sufficiently confident examinations was significantly higher for the transtemporal and transforaminal (both 80%) than for the extracranial approach (47%). The latter was mostly due to artificial signals derived from adjacent neck vessels. Conclusion: Levovist® constitutes a safe and highly effective diagnostic tool especially for the transtemporal and transforaminal neurosonographical imaging. By means of a differentiated application of echocontrast agents, its cost-effectiveness can be increased and the need for other potential invasive and expansive neuroimaging methods can be further reduced.

Original languageGerman
Pages (from-to)466-473
Number of pages8
JournalFortschritte der Neurologie Psychiatrie
Volume66
Issue number10
Publication statusPublished - Oct 1998

Fingerprint

Doppler Transcranial Ultrasonography
Diagnostic Imaging
Neuroimaging
Cost-Benefit Analysis
Ultrasonography
Neck
Color
SHU 508

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology

Cite this

Nabavi, D. G., Droste, D. W., Schulte-Altedorneburg, G., Kemény, V., Panzica, M., Weber, S., & Ringelstein, E. B. (1998). Klinische bedeutung der echokontrastverstarkung in der neurovaskularen diagnostik: Erfahrungsbericht nach einjahriger offener anwendungsstudie. Fortschritte der Neurologie Psychiatrie, 66(10), 466-473.

Klinische bedeutung der echokontrastverstarkung in der neurovaskularen diagnostik : Erfahrungsbericht nach einjahriger offener anwendungsstudie. / Nabavi, D. G.; Droste, D. W.; Schulte-Altedorneburg, G.; Kemény, V.; Panzica, M.; Weber, S.; Ringelstein, E. B.

In: Fortschritte der Neurologie Psychiatrie, Vol. 66, No. 10, 10.1998, p. 466-473.

Research output: Contribution to journalArticle

Nabavi, DG, Droste, DW, Schulte-Altedorneburg, G, Kemény, V, Panzica, M, Weber, S & Ringelstein, EB 1998, 'Klinische bedeutung der echokontrastverstarkung in der neurovaskularen diagnostik: Erfahrungsbericht nach einjahriger offener anwendungsstudie', Fortschritte der Neurologie Psychiatrie, vol. 66, no. 10, pp. 466-473.
Nabavi, D. G. ; Droste, D. W. ; Schulte-Altedorneburg, G. ; Kemény, V. ; Panzica, M. ; Weber, S. ; Ringelstein, E. B. / Klinische bedeutung der echokontrastverstarkung in der neurovaskularen diagnostik : Erfahrungsbericht nach einjahriger offener anwendungsstudie. In: Fortschritte der Neurologie Psychiatrie. 1998 ; Vol. 66, No. 10. pp. 466-473.
@article{78aba64e1c1e4b3f96308810dfebb08b,
title = "Klinische bedeutung der echokontrastverstarkung in der neurovaskularen diagnostik: Erfahrungsbericht nach einjahriger offener anwendungsstudie",
abstract = "To evaluate the potential and limitations of echocontrast enhancement using Levovist{\circledR} in a non selected consecutive cohort of neurological patients with insufficient native ultrasound investigations. Methods: In 91 patients an indication for echocontrast application was seen after an insufficient extracranial (n = 17), transtemporal (n = 54), and transforaminal (n = 20) Doppler- und color-coded Duplex sonography. Levovist{\circledR} was injected at a concentration of 400 mg/ml and 200-400 mg/ml for the transcranial and extracranial approach, respectively. The effect of the echocontrast enhancement was assessed semiquantitatively with respect to signal enhancement, imaging quality, and diagnostic confidence. Results: In a total of 83 patients (91{\%}) the signal enhancement led to a moderate to high imaging quality allowing to reach 67 definite neurovascular diagnoses (74{\%}). In subgroup analysis, the amount of sufficiently confident examinations was significantly higher for the transtemporal and transforaminal (both 80{\%}) than for the extracranial approach (47{\%}). The latter was mostly due to artificial signals derived from adjacent neck vessels. Conclusion: Levovist{\circledR} constitutes a safe and highly effective diagnostic tool especially for the transtemporal and transforaminal neurosonographical imaging. By means of a differentiated application of echocontrast agents, its cost-effectiveness can be increased and the need for other potential invasive and expansive neuroimaging methods can be further reduced.",
author = "Nabavi, {D. G.} and Droste, {D. W.} and G. Schulte-Altedorneburg and V. Kem{\'e}ny and M. Panzica and S. Weber and Ringelstein, {E. B.}",
year = "1998",
month = "10",
language = "German",
volume = "66",
pages = "466--473",
journal = "Fortschritte der Neurologie Psychiatrie",
issn = "0720-4299",
publisher = "Georg Thieme Verlag",
number = "10",

}

TY - JOUR

T1 - Klinische bedeutung der echokontrastverstarkung in der neurovaskularen diagnostik

T2 - Erfahrungsbericht nach einjahriger offener anwendungsstudie

AU - Nabavi, D. G.

AU - Droste, D. W.

AU - Schulte-Altedorneburg, G.

AU - Kemény, V.

AU - Panzica, M.

AU - Weber, S.

AU - Ringelstein, E. B.

PY - 1998/10

Y1 - 1998/10

N2 - To evaluate the potential and limitations of echocontrast enhancement using Levovist® in a non selected consecutive cohort of neurological patients with insufficient native ultrasound investigations. Methods: In 91 patients an indication for echocontrast application was seen after an insufficient extracranial (n = 17), transtemporal (n = 54), and transforaminal (n = 20) Doppler- und color-coded Duplex sonography. Levovist® was injected at a concentration of 400 mg/ml and 200-400 mg/ml for the transcranial and extracranial approach, respectively. The effect of the echocontrast enhancement was assessed semiquantitatively with respect to signal enhancement, imaging quality, and diagnostic confidence. Results: In a total of 83 patients (91%) the signal enhancement led to a moderate to high imaging quality allowing to reach 67 definite neurovascular diagnoses (74%). In subgroup analysis, the amount of sufficiently confident examinations was significantly higher for the transtemporal and transforaminal (both 80%) than for the extracranial approach (47%). The latter was mostly due to artificial signals derived from adjacent neck vessels. Conclusion: Levovist® constitutes a safe and highly effective diagnostic tool especially for the transtemporal and transforaminal neurosonographical imaging. By means of a differentiated application of echocontrast agents, its cost-effectiveness can be increased and the need for other potential invasive and expansive neuroimaging methods can be further reduced.

AB - To evaluate the potential and limitations of echocontrast enhancement using Levovist® in a non selected consecutive cohort of neurological patients with insufficient native ultrasound investigations. Methods: In 91 patients an indication for echocontrast application was seen after an insufficient extracranial (n = 17), transtemporal (n = 54), and transforaminal (n = 20) Doppler- und color-coded Duplex sonography. Levovist® was injected at a concentration of 400 mg/ml and 200-400 mg/ml for the transcranial and extracranial approach, respectively. The effect of the echocontrast enhancement was assessed semiquantitatively with respect to signal enhancement, imaging quality, and diagnostic confidence. Results: In a total of 83 patients (91%) the signal enhancement led to a moderate to high imaging quality allowing to reach 67 definite neurovascular diagnoses (74%). In subgroup analysis, the amount of sufficiently confident examinations was significantly higher for the transtemporal and transforaminal (both 80%) than for the extracranial approach (47%). The latter was mostly due to artificial signals derived from adjacent neck vessels. Conclusion: Levovist® constitutes a safe and highly effective diagnostic tool especially for the transtemporal and transforaminal neurosonographical imaging. By means of a differentiated application of echocontrast agents, its cost-effectiveness can be increased and the need for other potential invasive and expansive neuroimaging methods can be further reduced.

UR - http://www.scopus.com/inward/record.url?scp=0031794663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031794663&partnerID=8YFLogxK

M3 - Article

C2 - 9825252

AN - SCOPUS:0031794663

VL - 66

SP - 466

EP - 473

JO - Fortschritte der Neurologie Psychiatrie

JF - Fortschritte der Neurologie Psychiatrie

SN - 0720-4299

IS - 10

ER -